Announced Date: 2024-12-18 (December 18, 2024)
Asset Name: HS-10535
Licensor: Hansoh Pharma (China)
Licensee (Buyer): MSD (Merck & Co., Inc. USA)
.
Asset Modality: Small Molecule
Asset Target: Oral GLP-1 receptor agonist (GLR-IRa)
Current Stage: preclinical
Scope of Authority:
Hansoh Pharma has granted MSD an exclusive global license to develop, manufacture and commercialize HS-10535.
.
Deal Detail:
Upfront payment of $112 million,
Milestone payments up to $1.9 billion,
Total up to $2.02 billion.
.
Link:
MSD Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
